Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HemNichMDS

Financiado

Functional and Molecular Analyses of the Interplay between Hematopoietic and Mes...

Functional and Molecular Analyses of the Interplay between Hematopoietic and Mesenchymal Niche Cells in Human Myelodysplastic Syndromes. Myelodysplastic syndromes (MDS) are heterogeneous clonal hematopoietic stem cell diseases mainly affecting the elderly (45/100,000 in >70 years). The prevalence of MDS is expected to rise mainly as a result of an aging population.... ver más

31/01/2022

Georg-Speyer-Haus

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-01-31

ERC-StG-2014: ERC Starting Grant

I+D

Cerrada hace 10 años

0% 100% 100%

2 Participantes

Georg-Speyer-Haus

1.50M€ | Lider

KERAFRIT

856.64K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

DRIMMS Dissecting the role of the immune microenvironment in the on... 181K€ Cerrado

BES-2014-068580 PAPEL DE DIDO EN LA DIFERENCIACION DE LAS CELULAS MADRE Y EL... 88K€ Cerrado

CNS2023-144908 Biología molecular y celular 400K€ Cerrado

ATR2023-144970 Fisiopatología de órganos y sistemas 843K€ Cerrado

SMART-AML SMART-AML: Shaping Marrow Adiposity to Redefine Treatment in... 188K€ Cerrado

PID2019-111348RB-I00 QUIMIOSENSIBILIZADORES COMO NUEVA APROXIMACION TERAPEUTICA P... 194K€ Cerrado

Duración del proyecto: 78 meses Fecha Inicio: 2015-07-08
Fecha Fin: 2022-01-31

Líder del proyecto

CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Myelodysplastic syndromes (MDS) are heterogeneous clonal hematopoietic stem cell diseases mainly affecting the elderly (45/100,000 in >70 years). The prevalence of MDS is expected to rise mainly as a result of an aging population. MDS is characterized by ineffective production of mature blood cells with peripheral cytopenias and the propensity to evolve to acute myeloid leukemia. Most MDS patients rely on continuous blood transfusions resulting in significant costs to healthcare systems and, most importantly, secondary effects leading to complications and patient deaths. The only potential curative treatment for MDS is hematopoietic stem cells (HSC) transplantation, which is limited to younger patients with suitable donors (<10% of MDS patients). Increasing evidence indicates that myeloid neoplasms can be triggered by abnormal functional properties of the bone marrow microenvironment in mice. However, it remains to be seen whether this also applies to human hematopoietic neoplasms. Our work revealed that patient-derived mesenchymal niche cells are essential to propagate human MDS HSCs in vivo, thus highlighting the crucial role of the niche in human MDS. Moreover, our data indicate that human MDS hematopoietic cells may educate their niche environment into a self-reinforcing one. The goal of our proposal is to decipher the interplay between hematopoietic and mesenchymal niche cells in human MDS, and to assess innovative means by which we could target diseased cells to improve MDS patient outcomes. We will perform a comprehensive molecular characterization of highly purified primary mesenchymal niche cells to define new prognostic/therapeutic niche factors in MDS. More importantly, we will take advantage of our unique xenograft model of MDS to translate our findings into groundbreaking novel therapeutic strategies for MDS patients, by disrupting essential niche/MDS stem cell interactions.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores